Back

Risk-guided disease management to prevent heart failure in adult cancer survivors of previous cardiotoxic cancer treatments (REDEEM) trial

29 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Managing heart failure across the cancer continuum: from risk prediction to survivorship Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Joshua Wong

Peter MacCallum Cancer Centre, Melbourne (Australia)

6 More presentations in this session

Presentation thumbnail
Persistence of guideline-directed medical therapy after heart failure hospitalisation in older adults with cancer
Doctor K. Daigo (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Quality of care and clinical outcomes in cancer patients presenting with acute heart failure
Doctor A. Cannata (London, GB)
Abstract Slides Video
Presentation thumbnail
A scalable electronic medical record–based risk score for predicting heart failure in cancer survivors: external validation of CHERISH
Doctor C. Soh (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Risk stratification and shap-derived mortality phenotypes in AMI and heart failure with breast/prostate cancer: NIS 2018–2022
Ms V. Godishala (Newark, US)
Abstract Slides Video
Presentation thumbnail
Prediction and personalized interpretation of risk for multiple cancer outcomes in patients with heart failure: a machine learning study
Miss Y. Qi (HK)
Abstract Slides Video

Access the full session

Session thumbnail
Managing heart failure across the cancer continuum: from risk prediction to survivorship

The Event

Event poster

ESC Congress 2026

29 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Session
Daily Highlights Programme - Heart Association of Thailand 2
28 August 2022
thumbnail
Congress Session
Evolving cardiovascular complications in cancer survivors: vascular and cardiometabolic risks
29 August 2026
thumbnail
Congress Presentation
An open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2 targeted therapy related cardiac dysfunction.
30 August 2026
thumbnail
Congress Presentation
Cardiac CARE - A randomised trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources